##semicolon##
хроническая сердечная недостаточность, ожирение, кардиометаболическая синдемия, хроническое низкоинтенсивное воспаление, инсулинорезистентность, HOMA-IR, С-реактивный белок, фактор некроза опухоли-α, адипокины, лептин, резистин, адипонектин, висцеральное ожирение, гемодинамические нарушения.##submission.citations##
1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639.
2. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032.
3. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380.
4. Schiattarella GG, Hill JA. Inflammation and heart failure: mechanisms and therapeutic implications. Nat Rev Cardiol. 2022;19(11):733-750.
5. Van Linthout S, Tschöpe C. Inflammation—cause or consequence of heart failure or both? Curr Heart Fail Rep. 2022;19(5):251-265.
6. Cooper LB, Hammill BG, Sharma PP, et al. Inflammation and heart failure: emerging concepts and therapeutic implications. J Am Coll Cardiol. 2021;77(15):1916-1931.
7. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2021;128(9):1451-1463.
8. Fernández-Real JM, Pickup JC. Innate immunity, inflammation and metabolic syndrome. Diabetologia. 2021;64(5):1037-1048.
9. Després JP. Visceral obesity, insulin resistance and cardiovascular disease. Eur Heart J. 2022;43(34):3241-3248.
10. Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity. Circulation. 2023;147(2):139-153.
11. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-e1010.
12. Koskinas KC, Van Craenenbroeck EM, Antoniades C, Blüher M, Carbone S, Eckel RH, et al. Obesity and cardiovascular disease: ESC Clinical Consensus Statement. Eur Heart J. 2024;45(38):4063-4098.
13. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2022;22(2):85-97.
14. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin and adipose tissue biology in cardiometabolic disease. Circ Res. 2021;128(2):181-201.
15. Ruiz-Hurtado G, Ruilope LM. Adiponectin, leptin and resistin in heart failure: mechanistic and clinical insights. Cardiovasc Drugs Ther. 2021;35(4): 575-589.
16. Van Linthout S, Tschöpe C. Adipokines and inflammation in obesity-related heart disease. ESC Heart Fail. 2021;8(5):3448-3460.
17. Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers. J Am Coll Cardiol. 2020;75(5):525-538.
18. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. JACC Heart Fail. 2021;9(8): 584-593.
19. Packer M. Leptin-aldosterone-neprilysin axis and cardiometabolic disease. Eur J Heart Fail. 2022;24(8):1291-1302.
20. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association. Circulation. 2022;145 (7):e251-e272.
21. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461.
22. Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, et al. Heart failure and cardiometabolic disease: from mechanisms to treatment. Lancet. 2022;400(10364):145-159.
23. Savarese G, Rosano GMC, Lund LH, et al. Heart failure and obesity: translational approaches and therapeutic opportunities. Eur J Heart Fail. 2025;27(2):215-230.
24. Borlaug BA. Obesity and heart failure with preserved ejection fraction: mechanisms and management. Nat Rev Cardiol. 2024;21(11):731-748.
25. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction. J Am Coll Cardiol. 2021;77(23):3004-3015.